Tears

U.S. Postal Service Celebrates the School Bus

Retrieved on: 
Thursday, January 5, 2023

HIGH POINT, N.C. , Jan. 5, 2023 /PRNewswire/ -- Whether it inspires excitement, tears, fears or nostalgia, the bright yellow bus that transports millions of students to classrooms across the United States every day is a cherished artifact of a common childhood experience. With the release of the School Bus additional ounce stamp, the U.S. Postal Service celebrates the iconic yellow school bus and its place in the nation's collective childhood.

Key Points: 
  • HIGH POINT, N.C. , Jan. 5, 2023 /PRNewswire/ -- Whether it inspires excitement, tears, fears or nostalgia, the bright yellow bus that transports millions of students to classrooms across the United States every day is a cherished artifact of a common childhood experience.
  • With the release of the School Bus additional ounce stamp, the U.S.
  • Postal Service celebrates the iconic yellow school bus and its place in the nation's collective childhood.

Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF

Retrieved on: 
Monday, January 2, 2023

SAN DIEGO, Dec. 29, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the submission of a supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to support the proposed indication for greatly expanded use of ZYNRELEF in soft tissue and orthopedic surgical procedures and a newly passed congressional bill that is anticipated to provide separate reimbursement outside of the packaged surgical payment for ZYNRELEF for almost 3 years.

Key Points: 
  • 2617, the omnibus spending bill approved by Congress last week includes a provision (SEC.
  • In two Phase 3 trials, ZYNRELEF demonstrated the ability to significantly increase the proportion of patients taking no opioids after surgery and we believe it qualifies for this separate payment.
  • ZYNRELEF currently has pass-through status in the outpatient setting of care through March 31, 2025 and this provision should extend separate reimbursement outside of the packaged surgical payment through December 31, 2027.
  • Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.

New Documentary by Vruir Tadevosian Shows Impact of War on Armenian Children

Retrieved on: 
Friday, December 16, 2022

A new documentary film shares the continuing struggles and the stories of the children traumatized by the recent 44-day war over Nagorno Karabakh and the surrounding territories.

Key Points: 
  • A new documentary film shares the continuing struggles and the stories of the children traumatized by the recent 44-day war over Nagorno Karabakh and the surrounding territories.
  • Documentarian Vruir Tadevosian, a Southern California broadcaster, is available for interviews about the current humanitarian crisis and has film clips available for broadcast.
  • "The Tales of the Blue Sky" takes its viewer into the world of children ripped apart and traumatized by war.
  • This documentary also tells about the horrifying tragedy that children go through in conflict zones around the world.

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

Retrieved on: 
Wednesday, December 14, 2022

The full manuscript, titled “Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa,” will appear in the December 15, 2022 issue of the NEJM.

Key Points: 
  • The full manuscript, titled “Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa,” will appear in the December 15, 2022 issue of the NEJM.
  • The GEM-3 trial was a randomized, double-blind, intra-patient placebo-controlled multi-center trial designed to evaluate the efficacy and safety of B-VEC for the treatment of DEB.
  • In the trial, matched wounds receiving topical B-VEC or placebo were evaluated in 31 DEB patients over 26 weeks.
  • Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases.

Innovative Soft Tissue Healing Treatments Now Available for Chronic Pain Sufferers in Virginia and Mid-Atlantic Region

Retrieved on: 
Wednesday, December 14, 2022

SAM provides mechanical stimulation of tissue to facilitate the remodeling process every day for a more rapid and robust healing response.

Key Points: 
  • SAM provides mechanical stimulation of tissue to facilitate the remodeling process every day for a more rapid and robust healing response.
  • The ZetrOZ sam®x1 device increases blood vessel diameters to bring more oxygenated blood to the healing site, removing cytokine enzymes and cellular waste, and expediting the healing process.
  • "We're incredibly happy to see SAM technology and the sam®x1 device providing healing and relief in yet another setting," Lewis said.
  • ZetrOZ Systems is leading healing innovations in sports medicine and developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®).

Namida Lab Announces Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Friday, December 16, 2022

Namida Lab, the world leader in tear-based diagnostics, today announced that key research and developmental work on tear-based breast cancer biomarkers was presented at the San Antonio Breast Cancer Symposium (SABCS) on December 9, 2022, in San Antonio, Texas.

Key Points: 
  • Namida Lab, the world leader in tear-based diagnostics, today announced that key research and developmental work on tear-based breast cancer biomarkers was presented at the San Antonio Breast Cancer Symposium (SABCS) on December 9, 2022, in San Antonio, Texas.
  • Research and Development Scientist and co-author, Dr. Prashanth Ravishankar, presented the work on behalf of Namida Lab.
  • Details of the poster presentation are as follows:
    Title: Development of an at-home breast health assessment test, to increase compliance with screening mammography using proteins from tears.
  • The San Antonio Breast Cancer Symposium is attended by a broad international audience from over 90 countries of academic and private physicians and researchers.

Franklin Center’s Holiday Tips for Keeping the Season Festive for Those with Sensory Sensitivity or on the Spectrum

Retrieved on: 
Wednesday, December 14, 2022

Here are some tips from the neurodiversity experts at Franklin Therapy , a mental and behavioral health clinic thats part of Franklin Center , for helping your neurodiverse child navigate the season.

Key Points: 
  • Here are some tips from the neurodiversity experts at Franklin Therapy , a mental and behavioral health clinic thats part of Franklin Center , for helping your neurodiverse child navigate the season.
  • For those on the spectrum or with other neurodiversities, though, change can be hard.
  • During holiday school breaks, those with sensory sensitivity may become overstimulated, said Katie Thormodsgaard, MSW, LICSW, Director for Franklin Therapy.
  • And when go to events, create a Holiday Bag full of their favorite calming fidgets, books, headphones, and other items.

Bayonetta Origins: Cereza and the Lost Demon Coming to Nintendo Switch on March 17, 2023

Retrieved on: 
Friday, December 9, 2022

During this years Game Awards ceremony, Nintendo debuted two world premiere trailers for games coming to the Nintendo Switch system.

Key Points: 
  • During this years Game Awards ceremony, Nintendo debuted two world premiere trailers for games coming to the Nintendo Switch system.
  • The first was the reveal of Bayonetta Origins: Cereza and the Lost Demon , a new take on the Bayonetta series starring Cereza, a young apprentice witch before she would come to be called Bayonetta.
  • View the full release here: https://www.businesswire.com/news/home/20221208006112/en/
    The Bayonetta Origins: Cereza and the Lost Demon game, a new take on the Bayonetta series, launches for Nintendo Switch on March 17, 2023.
  • In fact, a brief playable teaser for Bayonetta Origins: Cereza and the Lost Demon can be accessed within the Bayonetta 3 game!

Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)

Retrieved on: 
Thursday, December 8, 2022

AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.

Key Points: 
  • AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.
  • Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the last dose.
  • SERENA-2 is a randomized, open-label, parallel group, multicenter Phase II trial evaluating camizestrant at several dose levels compared to FASLODEX in advanced ER-positive, HER2-negative breast cancer.
  • The primary endpoints are PFS defined by response evaluation criteria in solid tumors (RECIST) version 1.1 for 75mg camizestrant versus FASLODEX and for 150mg camizestrant versus FASLODEX.

Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer

Retrieved on: 
Thursday, December 8, 2022

CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.

Key Points: 
  • CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.
  • Capivasertib is an investigational oral treatment currently in Phase III trials for the treatment of multiple subtypes of breast cancer, prostate cancer and a Phase II trial for hematologic malignancies.
  • Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION).
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.